DJIA38904.04 307.06
S&P 5005204.34 57.13
NASDAQ16248.52 199.44
Russell 20002060.10 8.70
German DAX18163.94 -238.49
FTSE 1007911.16 -64.73
CAC 408061.31 -90.24
EuroStoxx 505013.35 -57.20
Nikkei 22538992.08 -781.06
Hang Seng16723.92 -1.18
Shanghai Comp3069.30 -5.66
KOSPI2714.21 -27.79
Bloomberg Comm IDX102.90 0.64
WTI Crude-fut91.17 0.01
Brent Crude-fut86.57 1.15
Natural Gas1.79 0.00
Gasoline-fut2.79 -0.01
Gold-fut2345.40 33.50
Silver-fut27.50 0.46
Platinum-fut940.60 -5.50
Palladium-fut1007.40 -23.60
Copper-fut423.60 1.85
Aluminum-spot1815.00 0.00
Coffee-fut212.50 5.75
Soybeans-fut1185.00 5.00
Wheat-fut567.25 11.00
Bitcoin67976.00 304.00
Ethereum USD3328.10 56.27
Litecoin98.71 0.69
Dogecoin0.18 0.00
EUR/USD1.0862 0.0007
USD/JPY151.72 -0.02
GBP/USD1.2678 0.0016
USD/CHF0.9044 -0.0014
USD IDX104.28 0.08
US 10-Yr TR4.4 0.091
GER 10-Yr TR2.406 0.007
UK 10-Yr TR4.064 -0.005
JAP 10-Yr TR0.771 -0.004
Fed Funds5.5 0
SOFR5.32 0

Sub Markets

Topics

Alternative Assets  + Latest News  + VC  | 
Clinical Trial Platform Paradigm Raises $203M in Debut Funding

Clinical Trial Platform Paradigm Raises $203M in Debut Funding

Paradigm, a technology company that aims to integrate clinical trials more broadly into the healthcare system, launched out of stealth with a $203 million series A funding round co-led by venture capital firms ARCH Venture Partners and General Catalyst.

F-Prime Capital, GV, LUX Capital, Mubadala Capital and Magnetic Ventures also jonied the round. American Cancer Society’s BrightEdge fund was a strategic investor.

The startup says it’s creating a technology-enabled platform to “make clinical trials a care option for all patients.” Paradigm also acquired Deep Lens, a patient recruitment platform for oncology-focused clinical trials.

“By rethinking how clinical trials are conducted and reducing the burden on health systems for participation, they’re democratizing access to clinical trials,” said Hemant Taneja, CEO and managing director of General Catalyst and board co-chair for Paradigm.

Other VC-backed companies in this space include Medable, a Silicon Valley startup that raised a $304 million Series D at a $2.1 billion valuation in 2021.

Connect

Inside The Story

Paradigm

About Joe Palmisano

Joe Palmisano is Editorial Director for Connect Money, where he brings nearly three decades experience of market insights as a financial journalist, analyst and senior portfolio manager for leading financial publications, advisory firms, and hedge funds. In his role as Editorial Director, Joe is responsible for the selection of content and creation of daily business news covering the financial markets, including Alternative Assets, Direct Investment and Financial Advisory services. Before joining Connect Money, Joe was a financial journalist for the Wall Street Journal, regularly publishing feature stories and trend pieces on the foreign exchange, global fixed income and equity markets. Joe parlayed his experience as a financial journalist into roles as a Senior Research Analyst and Portfolio Manager, writing daily and weekly market analysis and managing a FX and US equity portfolio. Joe was also a contributing writer for industry magazines and publications, including SFO Magazine and the CMT Association. Joe earned a B.S.B.A. in Finance from The American University. He holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.

New call-to-action